• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Obstacles to Optimal Antenatal Corticosteroid Administration to Eligible Patients.适宜患者产前皮质激素应用的障碍。
Am J Perinatol. 2024 May;41(S 01):e594-e600. doi: 10.1055/a-1925-1435. Epub 2022 Aug 16.
2
Antenatal corticosteroid timing: accuracy after the introduction of a rescue course protocol.产前皮质类固醇的使用时机:引入挽救疗程方案后的准确性
Am J Obstet Gynecol. 2016 Jan;214(1):120.e1-6. doi: 10.1016/j.ajog.2015.08.018. Epub 2015 Aug 15.
3
Missed opportunities for optimal antenatal corticosteroid timing in medically indicated preterm births.医学指征性早产中错过最佳产前皮质激素时机的情况。
J Matern Fetal Neonatal Med. 2021 Aug;34(15):2522-2528. doi: 10.1080/14767058.2019.1670159. Epub 2019 Oct 1.
4
Use of antenatal corticosteroids and tocolytic drugs in preterm births in 29 countries: an analysis of the WHO Multicountry Survey on Maternal and Newborn Health.29 个国家中产前皮质类固醇和保胎药物在早产中的使用:对世卫组织母婴健康多国调查的分析。
Lancet. 2014 Nov 22;384(9957):1869-1877. doi: 10.1016/S0140-6736(14)60580-8. Epub 2014 Aug 12.
5
Association of Antenatal Corticosteroid Exposure and Infant Survival at 22 and 23 Weeks.产前皮质类固醇暴露与 22 至 23 周龄婴儿存活率的关系。
Am J Perinatol. 2023 Dec;40(16):1789-1797. doi: 10.1055/s-0041-1740062. Epub 2021 Nov 28.
6
Optimal timing of antenatal corticosteroid administration and preterm neonatal and early childhood outcomes.产前皮质类固醇给药的最佳时机与早产儿新生儿和儿童早期结局。
Am J Obstet Gynecol MFM. 2020 Feb;2(1):100077. doi: 10.1016/j.ajogmf.2019.100077. Epub 2019 Dec 17.
7
Prenatal interventions for congenital diaphragmatic hernia for improving outcomes.用于改善先天性膈疝预后的产前干预措施。
Cochrane Database Syst Rev. 2015 Nov 27;2015(11):CD008925. doi: 10.1002/14651858.CD008925.pub2.
8
Reliable implementation of evidence: a qualitative study of antenatal corticosteroid administration in Ohio hospitals.可靠实施证据:俄亥俄州医院产前皮质类固醇治疗的定性研究。
BMJ Qual Saf. 2016 Mar;25(3):173-81. doi: 10.1136/bmjqs-2015-003984. Epub 2015 Jun 8.
9
Trends in receipt of single and repeat courses of antenatal corticosteroid administration among preterm and term births: A retrospective cohort study.早产和足月产中接受单剂和重复疗程产前皮质类固醇给药的趋势:一项回顾性队列研究。
Aust N Z J Obstet Gynaecol. 2017 Dec;57(6):643-650. doi: 10.1111/ajo.12657. Epub 2017 Jul 10.
10
The impact of the Antenatal Late Preterm Steroids trial on the administration of antenatal corticosteroids.产前晚期早产儿皮质类固醇试验对产前皮质类固醇给药的影响。
Am J Obstet Gynecol. 2022 Aug;227(2):280.e1-280.e15. doi: 10.1016/j.ajog.2022.03.037. Epub 2022 Mar 24.

引用本文的文献

1
Maternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone.母体使用MitoQ可预防产前地塞米松导致的CYP活性程序性改变。
Pharmaceutics. 2025 Feb 22;17(3):285. doi: 10.3390/pharmaceutics17030285.

本文引用的文献

1
Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation.委员会意见第713号:用于胎儿成熟的产前糖皮质激素治疗
Obstet Gynecol. 2017 Aug;130(2):e102-e109. doi: 10.1097/AOG.0000000000002237.
2
Clinical indication and timing of antenatal corticosteroid administration at a single centre.单中心产前皮质类固醇给药的临床指征和时机。
BJOG. 2016 Feb;123(3):409-14. doi: 10.1111/1471-0528.13730. Epub 2015 Oct 20.
3
Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012.1993 - 2012年极早产儿的护理实践、发病率及死亡率趋势
JAMA. 2015 Sep 8;314(10):1039-51. doi: 10.1001/jama.2015.10244.
4
Antenatal corticosteroid timing: accuracy after the introduction of a rescue course protocol.产前皮质类固醇的使用时机:引入挽救疗程方案后的准确性
Am J Obstet Gynecol. 2016 Jan;214(1):120.e1-6. doi: 10.1016/j.ajog.2015.08.018. Epub 2015 Aug 15.
5
Reliable implementation of evidence: a qualitative study of antenatal corticosteroid administration in Ohio hospitals.可靠实施证据:俄亥俄州医院产前皮质类固醇治疗的定性研究。
BMJ Qual Saf. 2016 Mar;25(3):173-81. doi: 10.1136/bmjqs-2015-003984. Epub 2015 Jun 8.
6
Association Between Antenatal Corticosteroid Administration-to-Birth Interval and Outcomes of Preterm Neonates.产前皮质类固醇给药至分娩间隔与早产儿结局的关系。
Obstet Gynecol. 2015 Jun;125(6):1377-1384. doi: 10.1097/AOG.0000000000000840.
7
Use and attitudes of obstetricians toward 3 high-risk interventions in MFMU Network hospitals.MFMU网络医院产科医生对3种高风险干预措施的使用情况及态度。
Am J Obstet Gynecol. 2015 Sep;213(3):398.e1-11. doi: 10.1016/j.ajog.2015.05.005. Epub 2015 May 6.
8
Regional variation in antenatal corticosteroid use: a network-level quality improvement study.产前皮质类固醇使用的区域差异:网络层面的质量改进研究。
Pediatrics. 2015 Feb;135(2):e397-404. doi: 10.1542/peds.2014-2177. Epub 2015 Jan 19.
9
Trends in optimal, suboptimal, and questionably appropriate receipt of antenatal corticosteroid prophylaxis.产前使用糖皮质激素预防性治疗的最佳、次优及可疑适当接受情况的趋势。
Obstet Gynecol. 2015 Feb;125(2):288-296. doi: 10.1097/AOG.0000000000000629.
10
Antenatal corticosteroid administration: understanding its use as an obstetric quality metric.产前皮质类固醇给药:了解其作为产科质量指标的应用。
Am J Obstet Gynecol. 2014 Feb;210(2):143.e1-7. doi: 10.1016/j.ajog.2013.09.024. Epub 2013 Sep 18.

适宜患者产前皮质激素应用的障碍。

Obstacles to Optimal Antenatal Corticosteroid Administration to Eligible Patients.

机构信息

Department of Obstetrics and Gynecology, Ohio State University, Columbus, Ohio.

The George Washington University Biostatistics Center, Washington, District of Columbia.

出版信息

Am J Perinatol. 2024 May;41(S 01):e594-e600. doi: 10.1055/a-1925-1435. Epub 2022 Aug 16.

DOI:10.1055/a-1925-1435
PMID:35973796
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10065956/
Abstract

OBJECTIVE

Administration of antenatal corticosteroids (ANCS) is recommended for individuals expected to deliver between 24 and 34 weeks of gestation. Properly timed administration of ANCS achieves maximal benefit. However, more than 50% of individuals receive ANCS outside the recommended window. This study aimed to examine maternal and hospital factors associated with suboptimal receipt of ANCS among individuals who deliver between 24 and 34 weeks of gestation.

STUDY DESIGN

Secondary analysis of the Assessment of Perinatal Excellence (APEX), an observational study of births to 115,502 individuals at 25 hospitals in the United States from March 2008 to February 2011, was conducted. Data from 3,123 individuals who gave birth to a nonanomalous live-born infant between 24 to 34 weeks of gestation, had prenatal records available at delivery, and data available on the timing of ANCS use were included in this analysis. Eligible individuals' ANCS status was categorized as optimal (full course completed >24 hours after ANCS but not >7 days before birth) or suboptimal (none, too late, or too early). Maternal and hospital-level variables were compared using optimal as the referent group. Hierarchical multinomial logistic regression models, with site as a random effect, were used to identify maternal and hospital-level characteristics associated with optimal ANCS use.

RESULTS

Overall, 83.6% (2,612/3,123) of eligible individuals received any treatment: 1,216 (38.9%) optimal and 1,907 (61.1%) suboptimal. Within suboptimal group, 495 (15.9%) received ANCS too late, 901 (28.9%) too early, and 511 (16.4%) did not receive any ANCS. Optimal ANCS varied depending on indication for hospital admission ( < 0.001). Individuals who were admitted with intent to deliver were less likely to receive optimal ANCS while individuals admitted for hypertensive diseases of pregnancy were most likely to receive optimal ANCS (10 vs. 35%). The median gestational age of individuals who received optimal ANCS was 31.0 weeks. Adjusting for hospital factors, hospitals with electronic medical records and who receive transfers have fewer eligible individuals who did not receive ANCS. ANCS administration and timing varied substantially by hospital, optimal frequencies ranged from 9.1 to 51.3%, and none frequencies from 6.1 to 61.8%. When evaluating variation by hospital site, models with maternal and hospital factors did not explain any of the variation in ANCS use.

CONCLUSION

Optimal ANCS use varied by maternal and hospital factors and by hospital site, indicating opportunities for improvement.

KEY POINTS

· Majority of individuals who deliver between 24 and 34 weeks of gestation do not receive properly timed antenatal corticosteroids.. · Optimal use of antenatal corticosteroids varies by maternal and hospital factors and hospital site.. · Significant variation in hospital sites regarding optimally timed administration of antenatal corticosteroids indicates opportunities for improvement..

摘要

目的

建议对预计在 24 至 34 周之间分娩的个体给予产前皮质激素(ANCS)。ANCS 的适当时间给药可达到最大的益处。但是,超过 50%的人在推荐的时间窗之外接受 ANCS。本研究旨在研究与 24 至 34 周之间分娩的个体接受 ANCS 不理想相关的产妇和医院因素。

研究设计

对来自美国 25 家医院的 115,502 名个体的围产期卓越评估(APEX)的二次分析,该研究于 2008 年 3 月至 2011 年 2 月进行。对 3,123 名在 24 至 34 周之间分娩非畸形活产儿的个体进行了数据分析,这些个体在分娩时具有产前记录,并且可以获得 ANCS 使用时间的数据。将个体的 ANCS 状态分为最佳(完全完成> 24 小时,但距出生前不超过 7 天)或不理想(无,过晚或过早)。使用最佳作为参考组,比较产妇和医院水平的变量。使用分层多项逻辑回归模型,以站点为随机效应,确定与最佳 ANCS 使用相关的产妇和医院水平特征。

结果

总体而言,83.6%(2,612/3,123)的合格个体接受了任何治疗:1,216(38.9%)最佳,1,907(61.1%)不理想。在不理想的群体中,有 495(15.9%)接受了过晚的 ANCS,901(28.9%)过早,511(16.4%)未接受任何 ANCS。最佳 ANCS 的使用取决于入院的原因(<0.001)。打算分娩的人接受最佳 ANCS 的可能性较小,而因妊娠高血压疾病入院的人接受最佳 ANCS 的可能性最大(10 比 35%)。接受最佳 ANCS 的个体的中位孕龄为 31.0 周。在调整医院因素后,具有电子病历和接受转院的医院中,没有接受 ANCS 的合格个体更少。ANCS 的给药和时间安排在医院之间有很大差异,最佳频率范围为 9.1%至 51.3%,无频率范围为 6.1%至 61.8%。在评估医院站点的差异时,带有产妇和医院因素的模型无法解释 ANCS 使用的任何差异。

结论

最佳的 ANCS 使用因产妇和医院因素以及医院地点而异,表明有改进的机会。

重点

·大多数在 24 至 34 周之间分娩的个体未接受适当时间的产前皮质激素治疗。·产前皮质激素的最佳使用因产妇和医院因素以及医院地点而异。·在优化产前皮质激素给药方面,医院之间存在显著差异,表明有改进的机会。